We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
-2.85%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.08B
AUM Growth
-$190M
Cap. Flow
-$78.5M
Cap. Flow %
-7.25%
Top 10 Hldgs %
76.04%
Holding
46
New
4
Increased
2
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$14.6M
2
CELC icon
Celcuity
CELC
+$10.2M
3
ABEO icon
Abeona Therapeutics
ABEO
+$9.4M
4
CRBP icon
Corbus Pharmaceuticals
CRBP
+$7.02M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$3.76M

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$46.7M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$20.8M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$16.4M
4
GTH
Genetron Holdings Limited ADS
GTH
+$10.9M
5
SVRA icon
Savara
SVRA
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLNO
1
DELISTED
Soleno Therapeutics
SLNO
$299M 27.58%
7,316,851
-1,101,242
-13% -$46.7M
GERN icon
2
Geron
GERN
$937M
$115M 10.66%
27,225,292
– –
HRMY icon
3
Harmony Biosciences
HRMY
$2.06B
$78.6M 7.26%
2,606,247
– –
SVA
4
DELISTED
Sinovac Biotech, Ltd
SVA
$76.3M 7.05%
11,800,000
– –
DYN icon
5
Dyne Therapeutics
DYN
$4.27B
$57.7M 5.33%
1,635,136
– –
AVDL
6
DELISTED
Avadel Pharmaceuticals
AVDL
$55.8M 5.16%
3,972,099
– –
VRNA
7
DELISTED
Verona Pharma
VRNA
$51.3M 4.74%
3,549,758
-60,419
-2% -$882K
TERN
8
DELISTED
Terns Pharmaceuticals
TERN
$42.1M 3.89%
6,182,992
-475,000
-7% -$2.88M
ALXO icon
9
ALX Oncology
ALXO
$268M
$25.4M 2.35%
4,220,048
– –
VRDN icon
10
Viridian Therapeutics
VRDN
$2.15B
$21.8M 2.02%
1,678,207
– –
ATXS
11
DELISTED
Astria Therapeutics
ATXS
$21.2M 1.96%
2,329,027
– –
SLN
12
Silence Therapeutics
SLN
$536M
$21M 1.94%
1,105,454
– –
OLMA icon
13
Olema Pharmaceuticals
OLMA
$1.01B
$20.3M 1.87%
1,873,704
– –
COGT icon
14
Cogent Biosciences
COGT
$6.83B
$18.9M 1.75%
2,244,941
– –
ERAS icon
15
Erasca
ERAS
$6.3B
$15.9M 1.47%
+6,756,756
New +$14.6M
TARS icon
16
Tarsus Pharmaceuticals
TARS
$2.57B
$15.4M 1.42%
565,550
– –
DCTH icon
17
Delcath Systems
DCTH
$401M
$14M 1.29%
1,666,746
– –
RZLT icon
18
Rezolute
RZLT
$468M
$12M 1.11%
2,797,704
– –
CELC icon
19
Celcuity
CELC
$4.02B
$10M 0.92%
+610,500
New +$10.2M
SERA icon
20
Sera Prognostics
SERA
$77.5M
$9.77M 0.9%
1,650,440
– –
CMPS
21
Compass Pathways
CMPS
$1.46B
$9.71M 0.9%
1,608,000
– –
ZLAB icon
22
Zai Lab
ZLAB
$2.1B
$9.21M 0.85%
531,198
– –
ORIC icon
23
Oric Pharmaceuticals
ORIC
$1.23B
$8.98M 0.83%
1,269,676
+419,995
+49% +$3.76M
RGLS
24
DELISTED
Regulus Therapeutics
RGLS
$8.93M 0.82%
5,000,000
– –
ABEO icon
25
Abeona Therapeutics
ABEO
$341M
$7.81M 0.72%
+1,842,751
New +$9.4M
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
RCYC
Richard C. Young & Co Newport, Rhode Island $1.21B AUM 38.41% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return

Vivo Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Vivo Capital held 46 positions worth $1.08B, down 15% from $1.27B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Vivo Capital withdrew a net $78.5M in Q2 2024, closing 4 positions and reducing 6 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $20.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Vivo Capital opened a new position in Erasca worth $15.9M.

  • Vivo Capital's largest Q2 2024 buy was Erasca: 6,756,756 shares worth $15.9M.
  • Vivo Capital added most to Oric Pharmaceuticals in Q2 2024, an estimated $3.76M increase.
  • Vivo Capital's biggest Q2 2024 reduction was Soleno Therapeutics, cutting an estimated $46.7M.
  • Vivo Capital fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $20.8M.
  • Vivo Capital's ten largest holdings make up 76% of its $1.08B portfolio in Q2 2024.
  • Vivo Capital opened 4 new positions and closed 4 in Q2 2024.
  • Vivo Capital's portfolio value fell 15% quarter-over-quarter to $1.08B.

Based on Vivo Capital's 13F filing for Q2 2024, filed 14 Aug 2024.